Prepare for the long haul of drug monitoring

Article metrics

Credit: FayFoto, Inc.

As concerns have emerged in recent years over medications such as Vioxx and now Avandia, the need to improve the surveillance of approved drugs has become increasingly apparent. To ensure the success of the drugs they develop, biomedical researchers should track a wider set of clinical endpoints in drug trials and prepare to distinguish between real and false risks suggested by long-term safety monitoring.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


  1. 1

    Committee on Ethical and Scientific Issues in Studying the Safety of Approved Drugs; Institute of Medicine. Ethical Issues in Studying the Safety of Approved Drugs: A Letter Report. (The National Academies, 2010).

Download references

Author information

Rights and permissions

Reprints and Permissions

About this article

Further reading